JP2011051993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011051993A5 JP2011051993A5 JP2010228241A JP2010228241A JP2011051993A5 JP 2011051993 A5 JP2011051993 A5 JP 2011051993A5 JP 2010228241 A JP2010228241 A JP 2010228241A JP 2010228241 A JP2010228241 A JP 2010228241A JP 2011051993 A5 JP2011051993 A5 JP 2011051993A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- day
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 22
- 238000001802 infusion Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- XBJLFHMAIQTBJX-JTQLQIEISA-N (4s)-5-amino-5-oxo-4-[(2-phenylacetyl)amino]pentanoic acid Chemical compound OC(=O)CC[C@@H](C(=O)N)NC(=O)CC1=CC=CC=C1 XBJLFHMAIQTBJX-JTQLQIEISA-N 0.000 claims description 6
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims description 6
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims 4
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 claims 1
- 229960005488 aceglutamide Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 50
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical group OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 6
- 229960003424 phenylacetic acid Drugs 0.000 description 6
- 239000003279 phenylacetic acid Substances 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 0 CCCC(C(O)=O)NC(*C)=* Chemical compound CCCC(C(O)=O)NC(*C)=* 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/121,567 US6258849B1 (en) | 1998-07-23 | 1998-07-23 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000560887A Division JP2002521329A (ja) | 1998-07-23 | 1999-07-02 | フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011051993A JP2011051993A (ja) | 2011-03-17 |
| JP2011051993A5 true JP2011051993A5 (enExample) | 2012-01-19 |
Family
ID=22397538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000560887A Pending JP2002521329A (ja) | 1998-07-23 | 1999-07-02 | フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理 |
| JP2010228241A Withdrawn JP2011051993A (ja) | 1998-07-23 | 2010-10-08 | フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000560887A Pending JP2002521329A (ja) | 1998-07-23 | 1999-07-02 | フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6258849B1 (enExample) |
| EP (1) | EP1098643B1 (enExample) |
| JP (2) | JP2002521329A (enExample) |
| KR (4) | KR100399658B1 (enExample) |
| CN (3) | CN1605334A (enExample) |
| AT (1) | ATE257378T1 (enExample) |
| AU (1) | AU759278B2 (enExample) |
| BR (1) | BR9912356A (enExample) |
| CA (1) | CA2336945C (enExample) |
| DE (1) | DE69914084T2 (enExample) |
| DK (1) | DK1098643T3 (enExample) |
| EA (1) | EA004179B1 (enExample) |
| ES (1) | ES2214866T3 (enExample) |
| ID (1) | ID28160A (enExample) |
| IL (1) | IL140848A (enExample) |
| NZ (1) | NZ509244A (enExample) |
| PL (1) | PL213698B1 (enExample) |
| PT (1) | PT1098643E (enExample) |
| WO (1) | WO2000004894A2 (enExample) |
| ZA (1) | ZA200100622B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127419A (en) * | 1998-11-23 | 2000-10-03 | Burzynski; Stanislaw R. | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis |
| ES2333337T3 (es) * | 2000-08-29 | 2010-02-19 | Biocon Limited | Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal. |
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| US7087219B2 (en) * | 2003-05-28 | 2006-08-08 | Stanislaw R. Burzynski | Toothpaste containing anticancer agents |
| US20060246016A1 (en) * | 2003-05-28 | 2006-11-02 | Burzynski Stanislaw R | Toothpaste containing anticancer agents |
| US7772108B2 (en) * | 2004-06-25 | 2010-08-10 | Samsung Electronics Co., Ltd. | Interconnection structures for semiconductor devices and methods of forming the same |
| DK1773767T3 (en) | 2004-07-07 | 2016-03-21 | Biocon Ltd | Synthesis of azo bound in immune regulatory relations |
| CA2575367A1 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| JP5116479B2 (ja) | 2004-11-26 | 2013-01-09 | ユーシーエル ビジネス ピーエルシー | オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物 |
| US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
| ES2928586T3 (es) | 2009-04-03 | 2022-11-21 | Ocera Therapeutics Inc | Fenilacetato de L-ornitina y métodos para elaborar el mismo |
| KR101715008B1 (ko) | 2009-06-08 | 2017-03-22 | 유씨엘 비즈니스 피엘씨 | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 |
| JP6087284B2 (ja) | 2010-10-06 | 2017-03-01 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンフェニルアセテートを製造するための方法 |
| DK3223829T3 (da) | 2014-11-24 | 2020-02-10 | Ucl Business Ltd | Behandling af sygdomme associeret med hepatisk stellat-celleaktivering under anvendelse af ammoniak-sænkende terapier |
| HK1249434A1 (zh) | 2015-08-18 | 2018-11-02 | Ocera Therapeutics, Inc. | 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失 |
| WO2017114686A1 (en) * | 2015-12-30 | 2017-07-06 | Nestec S.A. | Method for determining fat free body mass |
| US10624869B2 (en) | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
| CA3063134A1 (en) | 2017-05-11 | 2018-11-15 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
| IL272422B2 (en) * | 2017-06-12 | 2025-03-01 | R Burzynski Stanislaw | Methods for the treatment of leptomeningeal disease |
| US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
| US20230190694A1 (en) * | 2021-11-03 | 2023-06-22 | Stanislaw R. Burzynski | Compositions for and methods of precision cancer treatment |
| CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
| CN116491472B (zh) * | 2022-12-14 | 2024-07-26 | 上海交通大学医学院附属第九人民医院 | 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途 |
| WO2024263963A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating head and neck cancer |
| WO2024263960A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating lung cancer |
| WO2024263966A2 (en) * | 2023-06-21 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating pancreatic cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4470970A (en) | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
| US5244922A (en) * | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
| US5254587A (en) | 1990-09-04 | 1993-10-19 | Burzynski Stanislaw R | Methods for treating AIDS |
| US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| ATE310505T1 (de) | 1996-05-14 | 2005-12-15 | Stanislaw R Burzynski | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
-
1998
- 1998-07-23 US US09/121,567 patent/US6258849B1/en not_active Expired - Fee Related
-
1999
- 1999-07-02 EA EA200100168A patent/EA004179B1/ru not_active IP Right Cessation
- 1999-07-02 KR KR10-2001-7001021A patent/KR100399658B1/ko not_active Expired - Fee Related
- 1999-07-02 AU AU48542/99A patent/AU759278B2/en not_active Ceased
- 1999-07-02 PT PT99932179T patent/PT1098643E/pt unknown
- 1999-07-02 EP EP99932179A patent/EP1098643B1/en not_active Expired - Lifetime
- 1999-07-02 AT AT99932179T patent/ATE257378T1/de active
- 1999-07-02 BR BR9912356-8A patent/BR9912356A/pt not_active Application Discontinuation
- 1999-07-02 NZ NZ509244A patent/NZ509244A/xx not_active IP Right Cessation
- 1999-07-02 PL PL345959A patent/PL213698B1/pl unknown
- 1999-07-02 JP JP2000560887A patent/JP2002521329A/ja active Pending
- 1999-07-02 CN CNA2004100032827A patent/CN1605334A/zh active Pending
- 1999-07-02 CA CA002336945A patent/CA2336945C/en not_active Expired - Fee Related
- 1999-07-02 KR KR10-2003-7002799A patent/KR100417100B1/ko not_active Expired - Fee Related
- 1999-07-02 KR KR10-2003-7002798A patent/KR100414587B1/ko not_active Expired - Fee Related
- 1999-07-02 ID IDW20010174A patent/ID28160A/id unknown
- 1999-07-02 WO PCT/US1999/015017 patent/WO2000004894A2/en not_active Ceased
- 1999-07-02 CN CNB2004100616005A patent/CN100400039C/zh not_active Expired - Fee Related
- 1999-07-02 CN CNB99811314XA patent/CN1191064C/zh not_active Expired - Fee Related
- 1999-07-02 ES ES99932179T patent/ES2214866T3/es not_active Expired - Lifetime
- 1999-07-02 IL IL14084899A patent/IL140848A/xx not_active IP Right Cessation
- 1999-07-02 DK DK99932179T patent/DK1098643T3/da active
- 1999-07-02 DE DE69914084T patent/DE69914084T2/de not_active Expired - Lifetime
- 1999-07-02 KR KR10-2003-7002800A patent/KR100417101B1/ko not_active Expired - Fee Related
-
2001
- 2001-01-22 ZA ZA2001/00622A patent/ZA200100622B/en unknown
- 2001-05-22 US US09/863,035 patent/US6943192B2/en not_active Expired - Lifetime
-
2010
- 2010-10-08 JP JP2010228241A patent/JP2011051993A/ja not_active Withdrawn